Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2021-11-03 Capital/Financing Update
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces the "successful Initial Public Offering on the regulated market of Euronext Paris." It details the capital increase (€31.5m), the IPO price (€13.50 per share), subscription commitments, and the intended use of proceeds. This content directly relates to fundraising and capital structure changes, which aligns perfectly with the definition of a Capital/Financing Update (CAP). Although it mentions corporate governance changes, the primary focus and bulk of the announcement concern the successful completion and details of the IPO/capital raise.
2021-11-03 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the successful Initial Public Offering (IPO) of MaaT Pharma on Euronext Paris. Key elements include the announcement of the capital increase (€31.5 M), the offering price (€13.50 per share), the total demand (€36.3 M), and the commencement date for trading. This content strongly indicates a financing or capital market event. The most specific category for announcing fundraising or capital structure changes is 'Capital/Financing Update' (CAP). While it is a press release, its primary function is to detail the capital raising, not just announce the publication of a report (which would be RPA/RNS). The document also mentions governance changes contingent on the listing, but the core subject is the successful IPO and capital raise.
2021-11-03 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.